Ohmyhome Reports Results of 106% Growth in the First Half of 2024
Significant Revenue Growth: Ohmyhome Ltd. reported a 106% increase in revenues to S$4.5 million (US$3.3 million) for the first half of 2024, driven by strong performance across its business units and improved gross margins.
Improved Financial Position: The company's net loss decreased to S$2.3 million (US$1.7 million), with a narrowed EBITDA loss margin from -107% to -44%, while cash and cash equivalents increased to S$2.4 million (US$1.8 million).
Trade with 70% Backtested Accuracy
Analyst Views on OMH
About OMH
About the author
OM Holdings (ASX:OMH) Shares Plunge 64% Over Three Years Amid EPS Loss
- Poor Stock Performance: OM Holdings' share price has plummeted by 64% over the past three years, reflecting significant challenges faced by the company that have undermined long-term investor confidence.
- Short-term Losses Intensify: In the last year alone, OM Holdings' stock has dropped by 29%, indicating that new investors are also experiencing severe financial difficulties, which could impact future financing capabilities.
- Declining Profitability: Concurrent with the stock price decline, OM Holdings' earnings per share (EPS) has significantly fallen, even resulting in a loss, making EPS a less reliable metric for assessing company performance.
- Market Performance Comparison: While the overall market gained about 10%, OM Holdings investors faced a total loss of 28%, suggesting a weakening competitive position and diminishing market confidence in the company.
This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Analyst Downgrades: Several Wall Street analysts have downgraded their ratings on various stocks, including Packaging Corporation of America (from Buy to Hold), Sarepta Therapeutics (from Neutral to Sell), and Angi Inc. (from Market Outperform to Market Perform).
Price Target Adjustments: Along with downgrades, analysts have also lowered price targets for these companies, with notable reductions for Sarepta Therapeutics from $40 to $10 and PROS Holdings from $27 to $18.
US Stocks Mixed; JM Smucker Shares Plunge After Q4 Results
U.S. Stock Market Performance: U.S. stocks showed mixed results with the Nasdaq gaining 0.1%, while the Dow fell slightly. Notable movements included a 10% drop in shares of J.M. Smucker after disappointing financial results, and significant gains for Carisma Therapeutics and NuCana.
Global Market Trends: European and Asian markets closed mixed, with slight gains in some indices like Spain's IBEX 35 and Japan's Nikkei, while others like Germany's DAX and China's Shanghai Composite saw declines. The NFIB Small Business Optimism Index rose, indicating improved sentiment among small businesses.
3 Penny Stocks to Watch Now, 6/10/25
Penny Stocks to Watch: Klotho Neurosciences, Know Labs, and Ohmyhome Limited are highlighted as top penny stocks on June 10, 2025, based on their significant Dollar Volume and recent stock price surges, with Klotho experiencing a remarkable increase of over 787% due to promising pre-clinical trial data.
Company Developments: Know Labs is set to undergo leadership changes following an acquisition agreement, while Ohmyhome Limited's stock surged by 299.3% despite no specific news, although it is trending down in pre-market trading.
Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Circle Internet Group IPO Success: Circle Internet Group's shares surged over 29% following its IPO, opening at $69 and reaching a pre-market trading price of $126.99, reflecting strong market interest in the USDC stablecoin issuer.
Pre-Market Trading Highlights: Several stocks experienced significant movements in pre-market trading, with Klotho Neurosciences rising 123.5% due to positive gene therapy news, while Sunnova Energy saw a decline of 27% after disappointing performance results.
Ohmyhome Reports 118% Revenue Growth for Fiscal Year 2024
Financial Performance: Ohmyhome Ltd. reported a total revenue increase of 118% to S$10.9 million for the fiscal year ending December 31, 2024, with significant growth in all business segments and a narrowed net loss of S$4.4 million.
Operational Highlights: The company improved its gross margin to 40.5%, reduced EBITDA loss to S$3.4 million, and strengthened shareholders' equity from S$4.0 million to S$6.3 million, while focusing on scaling core businesses through enhanced marketing and AI engagement strategies.
OM Holdings (ASX:OMH) Shares Plunge 64% Over Three Years Amid EPS Loss
- Poor Stock Performance: OM Holdings' share price has plummeted by 64% over the past three years, reflecting significant challenges faced by the company that have undermined long-term investor confidence.
- Short-term Losses Intensify: In the last year alone, OM Holdings' stock has dropped by 29%, indicating that new investors are also experiencing severe financial difficulties, which could impact future financing capabilities.
- Declining Profitability: Concurrent with the stock price decline, OM Holdings' earnings per share (EPS) has significantly fallen, even resulting in a loss, making EPS a less reliable metric for assessing company performance.
- Market Performance Comparison: While the overall market gained about 10%, OM Holdings investors faced a total loss of 28%, suggesting a weakening competitive position and diminishing market confidence in the company.
This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Analyst Downgrades: Several Wall Street analysts have downgraded their ratings on various stocks, including Packaging Corporation of America (from Buy to Hold), Sarepta Therapeutics (from Neutral to Sell), and Angi Inc. (from Market Outperform to Market Perform).
Price Target Adjustments: Along with downgrades, analysts have also lowered price targets for these companies, with notable reductions for Sarepta Therapeutics from $40 to $10 and PROS Holdings from $27 to $18.
US Stocks Mixed; JM Smucker Shares Plunge After Q4 Results
U.S. Stock Market Performance: U.S. stocks showed mixed results with the Nasdaq gaining 0.1%, while the Dow fell slightly. Notable movements included a 10% drop in shares of J.M. Smucker after disappointing financial results, and significant gains for Carisma Therapeutics and NuCana.
Global Market Trends: European and Asian markets closed mixed, with slight gains in some indices like Spain's IBEX 35 and Japan's Nikkei, while others like Germany's DAX and China's Shanghai Composite saw declines. The NFIB Small Business Optimism Index rose, indicating improved sentiment among small businesses.
3 Penny Stocks to Watch Now, 6/10/25
Penny Stocks to Watch: Klotho Neurosciences, Know Labs, and Ohmyhome Limited are highlighted as top penny stocks on June 10, 2025, based on their significant Dollar Volume and recent stock price surges, with Klotho experiencing a remarkable increase of over 787% due to promising pre-clinical trial data.
Company Developments: Know Labs is set to undergo leadership changes following an acquisition agreement, while Ohmyhome Limited's stock surged by 299.3% despite no specific news, although it is trending down in pre-market trading.
Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Circle Internet Group IPO Success: Circle Internet Group's shares surged over 29% following its IPO, opening at $69 and reaching a pre-market trading price of $126.99, reflecting strong market interest in the USDC stablecoin issuer.
Pre-Market Trading Highlights: Several stocks experienced significant movements in pre-market trading, with Klotho Neurosciences rising 123.5% due to positive gene therapy news, while Sunnova Energy saw a decline of 27% after disappointing performance results.
Ohmyhome Reports 118% Revenue Growth for Fiscal Year 2024
Financial Performance: Ohmyhome Ltd. reported a total revenue increase of 118% to S$10.9 million for the fiscal year ending December 31, 2024, with significant growth in all business segments and a narrowed net loss of S$4.4 million.
Operational Highlights: The company improved its gross margin to 40.5%, reduced EBITDA loss to S$3.4 million, and strengthened shareholders' equity from S$4.0 million to S$6.3 million, while focusing on scaling core businesses through enhanced marketing and AI engagement strategies.
